BICYCLE THERAPEUTICS PLC
For the period ended Jun 30, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 30, 2026
BCYC$3.69-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Six Months Ended | ||||||
| · · June 30, | ||||||
| · · 2026 · · 2025 | ||||||
| Cash flows from operating activities: · · · · · | ||||||
| Net loss | | $(111,158) | | $(139,706) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Share-based compensation expense | | 13,334 | | 19,040 | ||
| Depreciation and amortization | | 2,196 | | 3,330 | ||
| Deferred income tax provision (benefit) | | 85 | | | (1,647) | |
| Changes in operating assets and liabilities: | | | | | | |
| Research and development incentives receivable | | (12,556) | | (20,781) | ||
| Prepaid expenses and other assets | | 660 | | (8,571) | ||
| Operating lease right‑of‑use assets | | 1,699 | | 2,235 | ||
| Accounts payable | | (3,897) | | 1,080 | ||
| Accrued expenses and other current liabilities | | (2,950) | | 972 | ||
| Operating lease liabilities | | (1,994) | | (2,656) | ||
| Deferred revenue | | (950) | | (12,452) | ||
| Net cash used in operating activities | | (115,531) | | (159,156) | ||
| Cash flows from investing activities: | | | | | ||
| Purchases of property and equipment | | (978) | | (1,102) | ||
| Net cash used in investing activities | | (978) | | (1,102) | ||
| Cash flows from financing activities: | | | | | ||
| Proceeds from the exercise of share options and settlement of restricted share units | | | 13 | | | 3 |
| Payments of finance lease obligations | | | (117) | | | (89) |
| Net cash used in financing activities | | (104) | | (86) | ||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | | (1,993) | | 2,275 | ||
| Net decrease in cash, cash equivalents and restricted cash | | (118,606) | | (158,069) | ||
| Cash, cash equivalents and restricted cash at beginning of period | | 628,715 | | 880,067 | ||
| Cash, cash equivalents and restricted cash at end of period | | $510,109 | | $721,998 | ||
| Reconciliation of cash, cash equivalents and restricted cash | | | | | | |
| Cash and cash equivalents | | $510,052 | | $721,451 | ||
| Restricted cash in prepaid expenses and other current assets | | | — | | | 547 |
| Restricted cash in other assets | | | 57 | | | — |
| Total cash, cash equivalents and restricted cash | | $510,109 | | $721,998 | ||
| Supplemental disclosure of cash flow information | | | | | ||
| Cash paid for interest on finance lease obligations | | $43 | | $44 | ||
| Cash paid for (received from) income taxes | | $406 | | $(1,121) | ||
| Cash paid for amounts included in the measurement of operating lease liabilities | | $2,468 | | $2,956 | ||
| Changes in purchases of property and equipment in accounts payable and accrued expenses | | $(39) | | $271 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.